Thursday, November 20, 2008

Mixed fortunes for Caraco

Caraco Pharmaceutical Laboratories has found itself with mixed fortunes in recent weeks. According to an article in the Detroit News (see page 4), the firm has plans to boost production at its New Centre manufacturing plant next year with a US$22 million expansion that will see it take on another 600 members of staff, doubling the size of the firm. This is undoubtedly good news both for Caraco and for the Detroit area, and appears to show that this firm at least is confident that it can buck the trend of the looming recession currently threatening the United States and much of the world. The Detroit News’ article came just over a year after Michigan’s governor announced that Caraco was to invest some US$14.5 million in a 140,000 square foot expansion of its manufacturing facilities in Detroit, and these two events show Caraco to be in good health.

That impression was backed up in late October 2008, when Caraco reported its second quarter and six month results for its fiscal 2009 (see page 5). Caraco’s net sales jumped by nearly 200% for the latest second quarter compared to the previous one, and net sale jumped by just over 200% for the first half of the current fiscal year compared to fiscal 2008. Caraco’s second quarter fiscal 2009 results were nearly 18% higher than its first quarter results, which in turn were over 200% higher than the first quarter fiscal 2008 sales. For both its first and second quarter results, Caraco has said that its sales results have been largely down to sales of distributed products under its distribution and sales agreement with Sun Pharma. Clearly, Caraco is enjoying a period of excellent growth.

However, on 3rd November 2008, the company reported a potential spanner in the works. The FDA issued Caraco with a warning letter issued as a follow-up to the last FDA inspection of the Detroit facility in May 2008. At the time, Caraco responded to all of the observations made within 30 days and took corrective action. However, the new warning letter suggests that there were inadequate and untimely investigations by Caraco’s quality control unit; Caraco noted that the FDA considered some of its observations to be repeat observations. Caraco has naturally stressed that it will work to resolve the issues, but at the same time the firm has noted that the FDA could act by withholding approval of pending new drug applications listing the facility as the manufacturer. Were this to happen, it could upset Caraco’s future plans for the Detroit plant.

Ian Platts - Editor, World Generic Markets

Monday, October 20, 2008

Apotex ships first CAMR drugs to Rwanda

Apotex has announced that its first shipment of its triple combination HIV/AIDS drug, Apo-TriAvir, is to be shipped to Rwanda. The news marks the culmination of a long process to enable the Canadian firm to produce a generic cocktail comprising drugs still under patent protection in Canada for sale solely to Rwanda utilising Canada’s Access to Medicines Regime (CAMR), formerly known as the Jean Chrétien Pledge to Africa Act. So far, Rwanda has been the only country to take advantage of the regime, which Canada brought in to align its patent laws with the World Trade Organisation’s framework to enable generic copies of patented drugs to be shipped to countries in need.

Whilst Apotex has been understandably pleased with itself for seeing the process through, it has nonetheless been critical of the Access to Medicines Regime, noting that the regime is too complex and problematic. Apotex is clear that the regime needs to be changed in order for it to be workable, and has previously suggested that it would not be willing to utilise it again in the future. Indeed, the regime has come in for criticism since its conception for being too bureaucratic and long-winded by a number of organisations; the difficulties involved in using it can be seen by the fact that the law has been in place since 2004 and in force since 2005, yet this is the first time it has been used.

Clearly, the experiences of the one company that has used the regime would show that changes need to be made to it, and the Canadian Parliament would do well to take another look at the legislation, using Apotex’ experience to see what changes could be made. However, before being quick to condemn, it is worth noting that the regime was introduced after a great deal of consultation from organisations with interests across the spectrum of pharmaceutical manufacturing and distribution. It was created to try to balance the needs of access to affordable drugs against the necessity of protecting patent law, and so it is somewhat inevitable that a law that tries to keep contradictory forces balanced will be difficult to use. Whilst that does not mean that changes cannot be investigated, it does mean that the resulting process will never be likely to please all interested parties. It is also worth noting that however difficult Apotex has found the process, this is still the first time any such law has been used in the world, and Canada still deserves credit for being the first country to try to amend its laws to enable its pharmaceutical manufacturing skills to be used to help developing countries in need. Canada should move to cap this achievement by making the law more workable.i to represent it in Court in an attention-grabbing move. Nevertheless, the firm may need more than PR to help it out of its current predicament.

Ian Platts - Editor, World Generic Markets

Thursday, September 25, 2008

US FDA issues import alert for key Ranbaxy products

The US FDA has issued two warning letters to Ranbaxy Laboratories and an import alert for generic drugs produced by the company's Dewas and Paonta Sahib plants in India. The warning letters identify the Agency's concerns about deviations from US cGMP requirements, while the import alert covers more than 30 different generic drug products produced in multiple dosage forms at these two locations.

While the FDA noted that it was confident that other manufacturers could meet market demands, and no product recall had been issued, the Wall Street Journal has reported that some drug stores are looking for alternative suppliers and were nervous that if they did switch they would be liable for cost increases due to contract provisions. Meanwhile, other countries have started to look at bans. In New Zealand, for example, the Health Ministry's drug regulatory arm has said that it was checking with regulators abroad to see if audits since then had given it a clean bill of health, though like the FDA it noted that there were no concerns about the medicines themselves and that users should continue taking the drugs.

This is not the first time that Ranbaxy has been in hot water with US regulators, and represents the second time in less than three years FDA has issued a Warning Letter to Ranbaxy. In 2006, FDA cited the Indian firm for violations of US cGMP at its Paonta Sahib facility. Since then, Ranbaxy has been attempting to resolve the issue with US regulators. However, in 2007, US officials seized documents from Ranbaxy's US headquarters in New Jersey. Furthermore, in July 2008, the US Department of Justice claimed that the company submitted false information about stability and bioequivalence to support ANDAs for antiretrovirals distributed by the President’s Emergency Plan for AIDS Relief (PEPFAR) programme. Prominent Congressmen on the US House Committee on Energy and Commerce indicated at the time that they would commence a formal investigation into the Ranbaxy drug approvals and potential violations of GMP regulations.

Daiichi Sankyo, which agreed to acquire the majority of the voting capital of Ranbaxy in June, has yet to comment on the latest events, though both firms have previously stressed that the share purchase agreement is binding and final. North America is a significant market for Ranbaxy, however; the region constituted around 26% of the firm’s revenues in 2007. Ranbaxy is already looking aggressive in its attempts to overturn the FDA’s ruling, enlisting former New York mayor Rudy Giuliani to represent it in Court in an attention-grabbing move. Nevertheless, the firm may need more than PR to help it out of its current predicament.

Jonathan Way - Editor, World Generic Markets

Wednesday, September 3, 2008

Counterfeit definition debate causes concern in India

World Health Organization attempts to introduce a broader new definition of counterfeit medicines have come under fire from the Indian government. A draft resolution on the new definition was presented at the 61st World Health Assembly in May 2008; this has been the subject of intense discussion, as was a WHO Secretariat report on the matter. The change from the current terminology has been promoted by the International Medical Products Anti-Counterfeiting Taskforce, a WHO unit set up in 2006.

The new definition could cause the registration of drugs in various territories to be an issue, as countries could link the issue of substandard drugs with intellectual property infringement. A major concern of the countries such as India is that legitimate generic medicines may become targets in the enforcement of counterfeit goods. According to a Business Standard report, the Indian Pharmaceutical Association has expressed concern that generic medicines that are legal in some countries could be classified erroneously as fake. This, combined with tougher enforcement of intellectual property rights elsewhere in the world, could mean that goods passing in transit may be seized for being fake, on the grounds that they are not registered.

A decision on the matter is unlikely before May 2009. Before then however, the office of the Drug Controller General of India is likely to come up with its own definition to promote to the WHO; this would incorporate recommendations from domestic manufacturers and is therefore unlikely to be a radical departure from the existing definition.

Perhaps of even more concern to India and other countries in the South Asia region is the new Anti-Counterfeiting Trade Agreement (ACTA) being negotiated between the United States, the European Union, Japan, South Korea, Canada, Mexico, Australia and New Zealand. By negotiating between themselves, these countries could undermine the WHO discussions and could simply ignore India’s objections. Treaty negotiations are still at a preliminary stage however, and no draft has been released to date; while this is a good sign for India that agreement is still not close, the secrecy will not help to allay its fears.

Jonathan Way - Editor, World Generic Markets

Tuesday, August 12, 2008

Teva eyes new markets following Barr purchase; DOJ targets Ranbaxy

Teva Pharmaceutical Industries has elaborated on its recent purchase of Barr Pharmaceuticals. The deal, valued at US$7.5 billion, raises interesting questions about Teva’s new scope. The two firms held an acquisition luncheon a few days after the announcement, in which they emphasised the strong strategic fit between the two companies, its expanded product portfolio and pipeline and its increased presence in first-to-file/paragraph IV applications.

Most significantly, Teva discussed its strengthened presence in key global markets; post-takeover, Teva will be able to offer direct sales in more than 60 countries. Eastern and Central Europe were highlighted as areas of strength for the combined firm. Barr and Teva combined would have been ranked fifth in Germany, third in Poland, ninth in Russia and first in Croatia in 2007. The new presence in Europe will be complemented by Teva’s new Spanish capabilities, following the successful completion of Teva’s Bentley Pharmaceutical purchase.

As for future growth opportunities, Teva CEO Shlomo Yanai noted in an interview with the Financial Times that he is now keen to forge a joint venture in Japan to capitalise on the country’s fast-growing generics market. "Right now Japan is more ripe for generics, (but still) difficult to break into," Yanai commented. Japan has traditionally been reluctant to accept generic medicines; the government has been keen to change habits, however, in an attempt to reduce medical costs. Recent rule changes compel generic substitution unless a doctor specifically requests a patented drug on the prescription form.

Any attempt by Yanai and Teva to get into the Japanese generics market is likely to come after Ranbaxy’s entrance via Daiichi Sankyo, which is in the process of buying the Indian firm. The deal between the two is still on track, in spite of recent allegations from the US Department of Justice against Ranbaxy. The DOJ claims that the company submitted false information about stability and bioequivalence to support ANDAs for antiretrovirals distributed by the President’s Emergency Plan for AIDS Relief (PEPFAR) programme. Prominent Congressmen in the US House Committee on Energy and Commerce have now indicated that it will soon commence a formal investigation into the Ranbaxy drug approvals and potential violations of GMP regulations. The moves have seemingly not deterred Daiichi however, which has been keen to stress that its share purchase agreement with Ranbaxy is binding and final.

Jonathan Way - Editor, World Generic Markets

Tuesday, August 5, 2008

Authorised generic deals come to the fore

The end of June saw a spate of authorised generic deals in the United States. On 24th June, Barr Laboratories entered into supply and licensing agreements for authorised generic versions of Bayer's Yasmin and YAZ (both drospirenone + ethinyloestradiol) oral contraceptive (OC) products. Under the Yasmin agreement, Bayer will supply Barr with an authorised generic version for launch on 1st July 2008; several years earlier than the last-to-expire Bayer patent listed in the FDA's Orange Book. In March, the US District Court for the District of New Jersey ruled in favour of Barr, in the challenge of the patent listed by Bayer's Yasmin product.

On 30th June 2008, under a supply agreement with Solvay Pharmaceuticals, Watson Pharmaceuticals launched an authorised generic dronabinol. Dronabinol is a generic version of Unimed Pharmaceuticals' (Solvay) Marinol capsules. Under the terms agreed, Solvay will supply the dronabinol capsules to the company's subsidiary, Watson Pharma, which will market, sell and distribute the product in the United States. Solvay will receive a share of the profits from Watson's sales of the generic product in the US market. Further details have not been disclosed.
On the same day, Janssen, a division of Ortho-McNeil-Janssen Pharmaceuticals (Johnson & Johnson), launched an authorised generic version of its antipsychotic agent, Risperdal (risperidone), through Patriot Pharmaceuticals (McNeil-PPC [J&J]). This development is a reaction to the FDA granting final approval for Teva Pharmaceutical Industries' ANDA to market a generic version of the drug. As the first company to file an ANDA containing a Paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing exclusivity and shipment has commenced. Generic risperidone could hurt J&J badly, as sales of the Risperdal franchise totalled US$4,549 million in 2007, accounting for 18.3% of pharmaceutical revenue.

The past three years have seen a growing number of authorised generic agreements in the USA; this recent sudden flurry may create more interest in Congress. The last two sessions of Congress have seen attempts at legislation to ban the practice; S. 438 currently languishes at committee stage in the Senate. The long-anticipated publication of an FTC report on the matter may provide a tipping point in support for the legislation; this was anticipated in 2007, yet has still not materialised. Meanwhile, most branded companies now have a policy of issuing authorised generic licences; in the current economic climate, and with significant patent expiries on the horizon, the practice is unlikely to be halted any time soon.

Jonathan Way - Editor, World Generic Market

Tuesday, July 1, 2008

Daiichi shocks industry with Ranbaxy share deal

Daiichi Sankyo and Ranbaxy Laboratories have surprised the pharmaceutical industry by entering into a binding share purchase and share subscription agreement, which will eventually leave Daiichi with a controlling interest in the Indian firm. The deal values Ranbaxy at US$8.5 billion and the total transaction value is expected to be between US$3.4 billion to US$4.6 billion. Daiichi Sankyo and Ranbaxy highlighted the complementary business combination that the link-up would create, noting that it would leave Daiichi with an expanded global reach and strong growth potential by complementing proprietary drugs with generics. Daiichi also hinted that it may shift part of its production to India, commenting that it could achieve further cost competitiveness by optimising its new R&D and manufacturing facilities.

The move represents Daiichi Sankyo's first foray into generic drugs, and contrasts with the strategy adopted by its Japanese rivals: Takeda Pharmaceutical, for example, bought biotech firm Millennium Pharmaceuticals in April, while Eisai bought speciality manufacturer MGI Pharma in December 2007. The Ranbaxy deal should bolster Daiichi’s revenues more quickly however, with income from the acquisition expected from the fiscal year after next.

Interestingly, Daiichi is following the model of Novartis by incorporating generic sales into its structure; this strategy has the obvious benefit of maximising the full pharmaceutical life-cycle of products, and also hedges the inherent riskiness of new molecules with a more steady supply of generics. The model follows long-term assumptions over the future of the industry, where a handful of global players will dominate, crowding out all competitors bar the smaller niche-orientated firms.

This major deal in many ways mirrors the divestiture of Merck Generics last spring. That deal saw a brandname manufacturer look to sell its generics division; the race to buy the firm was eventually won by Mylan Laboratories, which had to fight off competition from a number of other major generic firms. These included Ranbaxy, which was an early contender, along with Teva Pharmaceutical Industries and Actavis. At the time, it seemed these three companies would be in the forefront of bidding for the next big generics target; ironically, Ranbaxy itself has now become a target. That flurry of activity after the initial Merck Generics bid could indicate a similar bidding process for Ranbaxy; indeed rumours have since circulated that Pfizer may bid for the remaining shares. However, without the support of the Singh family, Ranbaxy’s largest and controlling shareholders, a counterbid may prove difficult. For now, Daiichi remains in the vanguard.

Jonathan Way - Editor, World Generic Markets